Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States

Michael L. Volk, Rebecca Burne, Annie Guérin, Sherry Shi, George J. Joseph, Zeev Heimanson, Maliha Ahmad

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)202-211
Number of pages10
JournalJournal of Medical Economics
Volume24
Issue number1
DOIs
StatePublished - 2021

ASJC Scopus Subject Areas

  • Health Policy

Keywords

  • Costs
  • hepatic encephalopathy
  • hospitalization
  • lactulose
  • rifaximin

Cite this